TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04616612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE (TM)
Description: Participants randomized to the refined SystemCHANGE™ intervention will receive 7 personalized sessions with a nurse-interventionist (session 1 virtual face-to-face, sessions 2-7 via phone) and weekly feedback MMS message reports delivered to mobile phones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants randomized to attention control will receive nurse-led kidney disease self-care education based on materials developed by The National Institute of Diabetes and Digestive and Kidney Diseases and The National Kidney Foundation. Similar to the intervention, participants will receive one virtual visit from the nurse-interventionist and 6 phone calls (weeks 2, 3, 4, 5, 6 and 7) and weekly educational MMS messages delivered by mobile phone.
Study: NCT05681832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch.
Study: NCT06570278

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WGS coupled with MCM
Description: Whole genome will be screened and analysis will focus on pathogenic and likely pathogenic variants. The list of variants of interest will be recorded until examination and discussion during the MCM. MCM will edit a final synthesis concerning the pathogenicity of identified variants.
Study: NCT06572111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100 (C-14) formulation 1
Description: BI 1839100 (C-14) formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100 (C-14) formulation 2
Description: BI 1839100 (C-14) formulation 2
Study: NCT06067581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SENL103
Description: Patients will be treated with BCMA CAR-T cells
Study: NCT06037018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CC312
Description: Doses from 0.3 to 45 µg/dose by intravenous infusion
Study: NCT06296472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: -the experimental group will carry out a program of eccentric exercises following the infiltration and will also wear the wrist brace for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: -the standard group will carry out a program of generic exercises following the infiltration and will also wear the wrist brace for 4 weeks.
Study: NCT06014879

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teen Videos
Description: All participants in the Teen Videos will create videos about living well with diabetes, which will be used in the the clinical trial of a new behavioral intervention.
Study: NCT06571383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide s.c(under the skin) once weekly.
Study: NCT06014879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 1 Doing Well (T1DW) Program
Description: Parent and youth will each have access to a version of the app. The study app activities include parents and youth:~* noticing what the youth does well for diabetes;~* setting and tracking a family diabetes goal in the app; and~* having a weekly meeting to review what the youth is doing well with diabetes and progress on the family diabetes goal.~Parents and youth will also have access to age-appropriate libraries of videos with diabetes-specific content.~Parents and youth will also have a conversation with the youth's diabetes care provider at a regularly scheduled diabetes appointment at participating hospital sites.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Care Provider Intervention Delivery
Description: Providers will use data-driven youth profiles to discuss youths' diabetes-related strengths and self-management behaviors during a diabetes care visit. This intervention will occur with the parents and youth once in the 6-month period. After each visit, providers will complete a questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes-Related Information and Resources Program
Description: Parent and youth will receive diabetes-related information and resources in the form of electronic handouts. They will receive one handout per month by email during the 6-month intervention period. These handouts include a variety of diabetes-related topics curated by the study team. Handouts will not include any specific information about the youth's health.
Study: NCT06280391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab (SAR440340)
Description: Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab (SAR440340)
Description: Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
Study: NCT05394701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 LipoMicel® soft gels
Description: A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RxOmega-3 soft gels (Enteric)
Description: A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Complete soft gels (Non-Enteric)
Description: A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Study: NCT06280391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
Study: NCT06417541

Intervention type: DIAGNOSTIC_TEST
Intervention: Diseased patients with an indwelling central venous catheter who is referred to autopsy
Description: Photon counting CT is performed and the results are compared to the results of the autopsy
Study: NCT04999085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care interventions
Description: Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
Study: NCT05118217

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study
Study: NCT06228235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS: rTMS is a form of non-invasive brain modulation. High-frequency rTMS will be administered. Pulses will be delivered at the frequency of 20Hz, in 50 trains of 40 pulses, 2000 pulses in total.~Behavioral priming with regulation of craving: During rTMS, participants will look at pictures either related or unrelated to smoking. When looking at pictures related to smoking, participants will either upregulate cravings by thinking about the immediate positive experience of smoking or downregulate cravings by thinking about long-term negative consequences of smoking. When looking at neutral pictures unrelated to smoking, participants will not regulate their cravings.
Study: NCT05977855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPSDiary
Description: The BPSDiary is a diary to register severity, hour, day and triggers of a number of BPSD (namely, agitation, aggression, delusions/hallucinations, insomnia, aberrant motor behavior).
Study: NCT06258707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxBoost IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LuxGood IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
Study: NCT06515626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell reinfusion
Description: Subjects were identified according to their benefit from the first treatment and target expression Whether to accept multiple returns; CAR-T cell reinfusion dose was 1\~10×106 cells/kg, and the reinfusion dose could be adjusted according to the tolerance of the subjects Usually intravenous infusion, but also according to the need for local interventional treatment or injection treatment
Study: NCT05757752

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Problem Solving Therapy and Integrated Care
Description: The intervention, will consist of problem solving therapy techniques to promote PAD self-management behaviors and depression/distress management.
Study: NCT06417541

Intervention type: RADIATION
Intervention: Living patients with an indwelling central venous catheter referred to a CT scan without iv contrast
Description: Patients will be investigated using a photon counting CT. Prior to the investigation patients will be investigated with ultrasound. The results from the two modalities will be compared
Study: NCT06097975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
Description: Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurosurgery and intracavitary injection nivolumab and ipililumab
Description: The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir
Study: NCT05348954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX-PLISSIT MODEL
Description: The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX-PLISSIT MODEL
Description: The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
Study: NCT05230355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 360 degrees subthreshold diode laser cyclophotocoagulation
Description: cyclophotocoagulation is applied along 360 degrees over pars plana

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 180 degrees subthreshold diode laser cyclophotocoagulation
Description: cyclophotocoagulation is applied over one hemisphere only along 180 degrees in a double arc fashion
Study: NCT06262646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Acceptance and Commitment Therapy
Description: Trained FACT interventionists will be guided by manualized FACT intervention to identify how many psychopathological processes need support and which ACT process(es) need to work on first, then offer parents process-matched ACT intervention strategies following the principles of FACT. The intervention strategies include ACT metaphors, experiential exercises, audio-guided mindfulness exercises, guided imagery exercises and value clarification exercises. The FACT steps in each session depend on the client's situation/stage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Both study groups will receive standard family support from collaborating NGOs.
Study: NCT06454123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTX-401
Description: Evidence-based treatments for obesity and binge eating
Study: NCT06451666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl Ophthalmic Solution
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.
Study: NCT05516238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case management
Description: Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
Study: NCT06326086

Intervention type: DRUG
Intervention: Chemotherapy drug
Description: Chemotherapy drug as prescribed by primary treating physician

Intervention type: DRUG
Intervention: Targeted Agent
Description: Targeted agents as prescribed by primary treating physician
Study: NCT06097975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary
Description: Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
Study: NCT06326086

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunotherapy as prescribed by primary treating physician
Study: NCT06153615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG (64 electrodes)
Description: EEG recording while awake, at rest then during an attentional cognitive test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG (64 electrodes)
Description: EEG recording while awake, at rest then during an attentional cognitive test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG (64 electrodes)
Description: EEG recording while awake, at rest then during an attentional cognitive test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive task (SART)
Description: Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive task (SART)
Description: Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive task (SART)
Description: Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry and eye tracking
Description: Study of pupil size and gaze path during the cognitive test (correlated with alertness)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pupillometry and eye tracking
Description: Study of pupil size and gaze path during the cognitive test (correlated with alertness)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry and eye tracking
Description: Study of pupil size and gaze path during the cognitive test (correlated with alertness)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoabdominal belts
Description: Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal belts
Description: Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoabdominal belts
Description: Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)
Study: NCT06458907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TricValve® Transcatheter Bicaval Valve System
Description: TricValve® Device (Device) Group subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TricValve® Transcatheter Bicaval Valve System
Description: TricValve® Device (Device) Group subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Optimal medical therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Description: Optimal medical therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Description: Optimal medical therapy
Study: NCT05772117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot-delivered interventions tailored to stage of changes
Description: Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chatbot-delivered standard interventions
Description: Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
Study: NCT05283577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: EA at 13 standardized acu-points that were chosen for their therapeutic effects: Shenting (GV24), Baihui (DU20), Sinshencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, Taichong (LIV3) bilateral
Study: NCT05734560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT
Description: D2C7-IT will be dosed at 166,075 ng in 36 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2141-V11
Description: 2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
Study: NCT06369246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo Radiation Therapy
Study: NCT06455605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT
Description: D2C7-IT will be dosed at 166,075 ng in 36 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2141 V11
Description: 2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
Study: NCT06632301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary hip replacement with cementless stem
Description: Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
Study: NCT05283577

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Electroacupuncture
Description: Non-disease related points with electrical stimulation: Pianli (LI6) bilateral, Wenliu (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8), Sidu (TE9) bilateral, Daheng (SP15) bilateral
Study: NCT06014996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) Therapy
Description: Patients randomized to thePulsed Field Ablation group will undergo PVI using the PFA system (Insight Medtech).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation（RAF）Therapy
Description: Patients randomized to Radiofrequency Ablation group will undergo PVI using the RFA system (Biosense Webster).
Study: NCT06488898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose tissue-derived mesenchymal stem cells
Description: Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention.
Study: NCT05588752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP block
Description: TAP block under ultrasound
Study: NCT05703334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tap
Description: Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tap
Description: Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
Study: NCT06259149

Intervention type: DRUG
Intervention: Nardraparin calcium injection
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day

Intervention type: DRUG
Intervention: Nardraparin calcium injection
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day